Moore KH - Search Results

1

Clinical pharmacokinetics of intranasal sumatriptan.

Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Fuseau E, et al. Among authors: moore kh. Clin Pharmacokinet. 2002;41(11):801-11. doi: 10.2165/00003088-200241110-00002. Clin Pharmacokinet. 2002. PMID: 12190330 Review.

2

Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.

Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE. Moore KH, et al. Cephalalgia. 1997 Jun;17(4):541-50. doi: 10.1046/j.1468-2982.1997.1704541.x. Cephalalgia. 1997. PMID: 9209776 Clinical Trial.

3

Clinical pharmacokinetics of lamivudine.

Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Johnson MA, et al. Among authors: moore kh. Clin Pharmacokinet. 1999 Jan;36(1):41-66. doi: 10.2165/00003088-199936010-00004. Clin Pharmacokinet. 1999. PMID: 9989342 Review.

4

The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.

Moore KH, Leese PT, McNeal S, Gray P, O'Quinn S, Bye C, Sale M. Moore KH, et al. Clin Ther. 2002 Apr;24(4):583-94. doi: 10.1016/s0149-2918(02)85134-7. Clin Ther. 2002. PMID: 12017403 Clinical Trial.

5

The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers.

Moore KH, McNeal S, Britto MR, Bye C, Sale M, Richardson MS. Moore KH, et al. Clin Ther. 2002 Nov;24(11):1887-901. doi: 10.1016/s0149-2918(02)80086-8. Clin Ther. 2002. PMID: 12501881 Clinical Trial.

6

Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT. Moore KH, et al. J Clin Pharmacol. 2001 Oct;41(10):1098-105. doi: 10.1177/00912700122012706. J Clin Pharmacol. 2001. PMID: 11583478 Clinical Trial.

7

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.

Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, Hussey EK. Moore KH, et al. Clin Pharmacol Ther. 1996 May;59(5):550-8. doi: 10.1016/S0009-9236(96)90183-6. Clin Pharmacol Ther. 1996. PMID: 8646826 Clinical Trial.

8

Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).

Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, Lemon SM, van der Horst CM. Moore KH, et al. Antimicrob Agents Chemother. 1995 Dec;39(12):2732-7. doi: 10.1128/AAC.39.12.2732. Antimicrob Agents Chemother. 1995. PMID: 8593010 Free PMC article. Clinical Trial.

9

A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration.

Peng AW, Hussey EK, Moore KH. Peng AW, et al. Among authors: moore kh. J Clin Pharmacol. 2000 Mar;40(3):242-9. doi: 10.1177/00912700022008900. J Clin Pharmacol. 2000. PMID: 10709152 Clinical Trial.

10

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE. Moodley D, et al. Among authors: moore kh. J Clin Pharmacol. 2001 Jul;41(7):732-41. doi: 10.1177/00912700122010636. J Clin Pharmacol. 2001. PMID: 11452705 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page